Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R Jr. McGuire WP, et al. Among authors: peterson p. BMC Cancer. 2018 Dec 27;18(1):1292. doi: 10.1186/s12885-018-5198-4. BMC Cancer. 2018. PMID: 30591028 Free PMC article. Clinical Trial.
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG. Scagliotti GV, et al. Among authors: peterson pm. Lung Cancer. 2014 Sep;85(3):408-14. doi: 10.1016/j.lungcan.2014.07.005. Epub 2014 Jul 16. Lung Cancer. 2014. PMID: 25088661 Free article. Clinical Trial.
Olaratumab-induced Biomarker Modulation in Sarcomas-Response.
Martín-Broto J, Peterson PM, Oakley GJ, Ceccarelli M, Jones RL. Martín-Broto J, et al. Mol Cancer Ther. 2021 Oct;20(10):2094. doi: 10.1158/1535-7163.MCT-21-0497. Mol Cancer Ther. 2021. PMID: 34607902 No abstract available.
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Paz-Ares L, et al. Among authors: peterson pm. J Clin Oncol. 2006 Mar 20;24(9):1428-34. doi: 10.1200/JCO.2005.04.3299. J Clin Oncol. 2006. PMID: 16549837 Clinical Trial.
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P. Scagliotti GV, et al. Among authors: peterson p. Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25. Eur J Cancer. 2009. PMID: 19473833 Clinical Trial.
1,676 results